ORMP : Summary for Oramed Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.24+0.14 (+2.30%)
At close: 4:00 PM EST
People also watch:
OHRPCNATVBLTCANFOCRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close6.10
Open6.08
Bid3.14 x 100
Ask7.45 x 1000
Day's Range5.98 - 6.34
52 Week Range5.60 - 10.51
Volume42,984
Avg. Volume34,993
Market Cap82.77M
Beta0.83
PE Ratio (TTM)-7.19
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 days ago

    ORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901

    On Nov. 29, Oramed (ORMP) announced that it successfully concluded a Phase Ib study of ORMD-0901, the Company’s proprietary oral GLP-1 analog. This ex-US Phase Ib study of ORMD-0901 is conducted in Israel. Currently Oramed is preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017.

  • PR Newswire3 days ago

    Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

    JERUSALEM, Nov. 29, 2016  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 analog. The Phase Ib study on type 2 diabetic patients showed ORMD-0901 to be safe and well tolerated, having no serious adverse events, adverse events or abnormal laboratory findings during the study.  In addition, the active oral GLP-1 arms of the study showed encouraging trending efficacy. Currently we are preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017," said Oramed CEO Nadav Kidron.

  • PR Newswire2 months ago

    Oramed Receives Additional $4 Million Milestone Payment From HTIT

    Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone is part of a previously-announced license and investment agreement between Oramed and HTIT, and follows recent milestone payments of $4 million and $6.5 million. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.